logo

For the Inventor, By the Inventor

Taipei, Taiwan

Ting-Jen Rachel Cheng

This inventor holds 16 USPTO granted patents and 5 published patent applications and 2 EPO patents, primarily in Influenza Vaccines. Top assignees: Academia Sinica, National Taiwan University, The Rockefeller University. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ting-Jen Rachel Cheng. Retrieved from https://idiyas.com/inventor/ting-jen-rachel-cheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 16 

% Patents Active = 87.5

 

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 59(Granted Patents)


Location History:

  • Yung-He, TW (2013)
  • Taipei, TW (2011 - 2023)
  • New Taipei, TW (2018 - 2024)

Company Filing History:

goldMedal16 out of 728 
 
Academia Sinica
 patents
silverMedal3 out of 1,398 
 
National Taiwan University
 patents
bronzeMedal1 out of 751 
 
The Rockefeller University
 patents
where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Vaccines
4(1)-Quinolone Derivatives
Proliferative Diseases
Infectious Diseases
Anticancer Activity
Osteoarthritis Treatment
Anti-Influenza Agents
Antibiotic Compositions
Sialyl Phosphate Donors
Flu Vaccines
Sialoside Arrays
Influenza Virus Detection
16 patents (USPTO):Explore Patents
1. 12178870 - Chimeric influenza vaccines (2024-12-31),
2. 12109207 - Methods of using 4(1)-quinolone derivatives (2024-10-08),
3. 11992525 - Chimeric influenza vaccines (2024-05-28),
4. 11919886 - 4,9-dioxo-4,9-dihydronaphtho[2,3-B]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases (2024-03-05),
5. 11918641 - Chimeric influenza vaccines (2024-03-05),
6. 11638705 - 4(1H)-quinolone derivatives and uses thereof (2023-05-02),
7. 11434229 - 4,9-dioxo-4,9-dihydronaphtho[2,3-b]furan-3-carboxamide derivatives and uses thereof for treating proliferative diseases and infectious diseases (2022-09-06),
8. 11332490 - Compounds and methods for treating osteoarthritis (2022-05-17),
9. 10765681 - Purine compounds possessing anticancer activity (2020-09-08),
10. 10130714 - Enhanced anti-influenza agents conjugated with anti-inflammatory activity (2018-11-20),
11. 9890111 - [object Object] (2018-02-13),
12. 8916540 - Antibiotic compositions and related screening methods (2014-12-23),
13. 8507660 - Alpha-selective sialyl phosphate donors for preparation of sialosides and sialoside arrays for influenza virus detection (2013-08-13),
14. 8354127 - [object Object] (2013-01-15),
15. 8105636 - [object Object] (2012-01-31),

Title: The Innovative Journey of Ting-Jen Rachel Cheng

Introduction: Ting-Jen Rachel Cheng, a pioneering inventor hailing from Taipei, Taiwan, has made significant contributions to the world of technology and innovation.

Latest Patents: Ting-Jen Rachel Cheng's latest patents focus on cutting-edge advancements in artificial intelligence and renewable energy technologies, showcasing his commitment to creating a sustainable future.

Career Highlights: With a career spanning over two decades, Ting-Jen Rachel Cheng has held key positions in renowned tech companies, leading groundbreaking research and development projects that have shaped the industry.

Collaborations: Throughout his career, Ting-Jen Rachel Cheng has collaborated with top researchers, engineers, and scientists from around the globe, fostering a culture of innovation and excellence in all his projects.

Conclusion: Ting-Jen Rachel Cheng's relentless pursuit of innovation and his passion for creating technologies that make a difference continue to inspire the next generation of inventors and entrepreneurs worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…